Literature DB >> 20193635

Two decades of clinical gene therapy--success is finally mounting.

Roland W Herzog1, Ou Cao, Arun Srivastava.   

Abstract

Human gene therapy has made substantial progress since the initiation of the first clinical trials 20 years ago. Here, we summarized important applications of gene transfer protocols in the treatment of various human diseases using different viral vectors. Recent successful trials on the treatment of ocular diseases and inherited immune deficiencies are particularly encouraging and have raised hopes that human gene therapy as a standard treatment option will finally become a reality. While immune responses and insertional mutagenesis pose obstacles for this novel form of molecular medicine, continuous progress suggests that a wider range of diseases can be treated with gene therapy in the future.

Entities:  

Mesh:

Year:  2010        PMID: 20193635      PMCID: PMC3586794     

Source DB:  PubMed          Journal:  Discov Med        ISSN: 1539-6509            Impact factor:   2.970


  33 in total

1.  Gene therapy restores vision in a canine model of childhood blindness.

Authors:  G M Acland; G D Aguirre; J Ray; Q Zhang; T S Aleman; A V Cideciyan; S E Pearce-Kelling; V Anand; Y Zeng; A M Maguire; S G Jacobson; W W Hauswirth; J Bennett
Journal:  Nat Genet       Date:  2001-05       Impact factor: 38.330

2.  Follistatin gene delivery enhances muscle growth and strength in nonhuman primates.

Authors:  Janaiah Kota; Chalonda R Handy; Amanda M Haidet; Chrystal L Montgomery; Amy Eagle; Louise R Rodino-Klapac; Danielle Tucker; Christopher J Shilling; Walter R Therlfall; Christopher M Walker; Steven E Weisbrode; Paul M L Janssen; K Reed Clark; Zarife Sahenk; Jerry R Mendell; Brian K Kaspar
Journal:  Sci Transl Med       Date:  2009-11-11       Impact factor: 17.956

3.  Correction of sickle cell disease in transgenic mouse models by gene therapy.

Authors:  R Pawliuk; K A Westerman; M E Fabry; E Payen; R Tighe; E E Bouhassira; S A Acharya; J Ellis; I M London; C J Eaves; R K Humphries; Y Beuzard; R L Nagel; P Leboulch
Journal:  Science       Date:  2001-12-14       Impact factor: 47.728

4.  Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency.

Authors:  D B Kohn; K I Weinberg; J A Nolta; L N Heiss; C Lenarsky; G M Crooks; M E Hanley; G Annett; J S Brooks; A el-Khoureiy
Journal:  Nat Med       Date:  1995-10       Impact factor: 53.440

Review 5.  Gene therapy: trials and tribulations.

Authors:  N Somia; I M Verma
Journal:  Nat Rev Genet       Date:  2000-11       Impact factor: 53.242

6.  Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.

Authors:  M Cavazzana-Calvo; S Hacein-Bey; G de Saint Basile; F Gross; E Yvon; P Nusbaum; F Selz; C Hue; S Certain; J L Casanova; P Bousso; F L Deist; A Fischer
Journal:  Science       Date:  2000-04-28       Impact factor: 47.728

7.  LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.

Authors:  S Hacein-Bey-Abina; C Von Kalle; M Schmidt; M P McCormack; N Wulffraat; P Leboulch; A Lim; C S Osborne; R Pawliuk; E Morillon; R Sorensen; A Forster; P Fraser; J I Cohen; G de Saint Basile; I Alexander; U Wintergerst; T Frebourg; A Aurias; D Stoppa-Lyonnet; S Romana; I Radford-Weiss; F Gross; F Valensi; E Delabesse; E Macintyre; F Sigaux; J Soulier; L E Leiva; M Wissler; C Prinz; T H Rabbitts; F Le Deist; A Fischer; M Cavazzana-Calvo
Journal:  Science       Date:  2003-10-17       Impact factor: 47.728

8.  T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.

Authors:  R M Blaese; K W Culver; A D Miller; C S Carter; T Fleisher; M Clerici; G Shearer; L Chang; Y Chiang; P Tolstoshev; J J Greenblatt; S A Rosenberg; H Klein; M Berger; C A Mullen; W J Ramsey; L Muul; R A Morgan; W F Anderson
Journal:  Science       Date:  1995-10-20       Impact factor: 47.728

9.  Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning.

Authors:  Alessandro Aiuti; Shimon Slavin; Memet Aker; Francesca Ficara; Sara Deola; Alessandra Mortellaro; Shoshana Morecki; Grazia Andolfi; Antonella Tabucchi; Filippo Carlucci; Enrico Marinello; Federica Cattaneo; Sergio Vai; Paolo Servida; Roberto Miniero; Maria Grazia Roncarolo; Claudio Bordignon
Journal:  Science       Date:  2002-06-28       Impact factor: 47.728

10.  Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients.

Authors:  C Bordignon; L D Notarangelo; N Nobili; G Ferrari; G Casorati; P Panina; E Mazzolari; D Maggioni; C Rossi; P Servida; A G Ugazio; F Mavilio
Journal:  Science       Date:  1995-10-20       Impact factor: 47.728

View more
  24 in total

Review 1.  Gene therapy: light is finally in the tunnel.

Authors:  Huibi Cao; Robert S Molday; Jim Hu
Journal:  Protein Cell       Date:  2012-01-10       Impact factor: 14.870

2.  Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D.

Authors:  Jerry R Mendell; Louise R Rodino-Klapac; Xiomara Q Rosales; Brian D Coley; Gloria Galloway; Sarah Lewis; Vinod Malik; Chris Shilling; Barry J Byrne; Thomas Conlon; Katherine J Campbell; William G Bremer; Laura E Taylor; Kevin M Flanigan; Julie M Gastier-Foster; Caroline Astbury; Janaiah Kota; Zarife Sahenk; Christopher M Walker; K Reed Clark
Journal:  Ann Neurol       Date:  2010-11       Impact factor: 10.422

3.  Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.

Authors:  Sid P Kerkar; Luis Sanchez-Perez; Shicheng Yang; Zachary A Borman; Pawel Muranski; Yun Ji; Dhanalakshmi Chinnasamy; Andrew D M Kaiser; Christian S Hinrichs; Christopher A Klebanoff; Christopher D Scott; Luca Gattinoni; Richard A Morgan; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Immunother       Date:  2011-05       Impact factor: 4.456

4.  The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver.

Authors:  Ashley T Martino; Masataka Suzuki; David M Markusic; Irene Zolotukhin; Renee C Ryals; Babak Moghimi; Hildegund C J Ertl; Daniel A Muruve; Brendan Lee; Roland W Herzog
Journal:  Blood       Date:  2011-04-07       Impact factor: 22.113

5.  Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer.

Authors:  Nagesh Pulicherla; Shen Shen; Swati Yadav; Kari Debbink; Lakshmanan Govindasamy; Mavis Agbandje-McKenna; Aravind Asokan
Journal:  Mol Ther       Date:  2011-03-01       Impact factor: 11.454

Review 6.  Exosomes and their Application in Biomedical Field: Difficulties and Advantages.

Authors:  Jafar Rezaie; Saeed Ajezi; Çığır Biray Avci; Mohammad Karimipour; Mohammad Hossein Geranmayeh; Alireza Nourazarian; Emel Sokullu; Aysa Rezabakhsh; Reza Rahbarghazi
Journal:  Mol Neurobiol       Date:  2017-05-11       Impact factor: 5.590

Review 7.  The retroviral vector family: something for everyone.

Authors:  Carina Elsner; Jens Bohne
Journal:  Virus Genes       Date:  2017-07-31       Impact factor: 2.332

8.  ACE2 and Ang-(1-7) confer protection against development of diabetic retinopathy.

Authors:  Amrisha Verma; Zhiying Shan; Bo Lei; Lihui Yuan; Xuan Liu; Takahiko Nakagawa; Maria B Grant; Alfred S Lewin; William W Hauswirth; Mohan K Raizada; Qiuhong Li
Journal:  Mol Ther       Date:  2011-07-26       Impact factor: 11.454

Review 9.  Gene delivery to bone.

Authors:  C H Evans
Journal:  Adv Drug Deliv Rev       Date:  2012-03-26       Impact factor: 15.470

Review 10.  State-of-the-art human gene therapy: part I. Gene delivery technologies.

Authors:  Dan Wang; Guangping Gao
Journal:  Discov Med       Date:  2014 Jul-Aug       Impact factor: 2.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.